# Ansa Biotechnologies

> Generated by All in One SEO v5.0.2.1, this is an llms.txt file, used by LLMs to index the site.

Unlock Breakthroughs with Enzymatic DNA synthesis

## Sitemaps

- [XML Sitemap](https://ansabio.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [News & Events](https://ansabio.com/news/)
- [Researchers Gain Faster Access to Complex DNA as Integrated DNA Technologies and Ansa Biotechnologies Expand Ordering Platform](https://ansabio.com/news-events/pr/researchers-gain-faster-access-to-complex-dna-as-integrated-dna-technologies-and-ansa-biotechnologies-expand-ordering-platform/): Streamlined workflow provides earlier visibility into synthesis feasibility, pricing, and fulfillment options.
- [What Makes a DNA Sequence Hard to Synthesize?](https://ansabio.com/dna101/what-makes-a-dna-sequence-hard-to-synthesize/): Sequence difficulty is rarely caused by synthesis alone. Pinpoint whether assembly, PCR, propagation, or verification is the true bottleneck.
- [Genome Editing and the DNA Inputs Behind Every Successful Edit](https://ansabio.com/dna101/genome-editing-and-the-dna-inputs-behind-every-successful-edit/): Understand what genome editing is and how it works in modern research. Learn why long, accurate DNA is critical for reliable editing outcomes.
- [How AI Is Changing DNA and Gene Design](https://ansabio.com/dna101/how-ai-is-changing-dna-and-gene-design/): Discover how AI is transforming DNA and gene design from optimization to generative sequence creation. Explore the impact on synthesis workflows.
- [Better Biosecurity for DNA Synthesis in the AI Era](https://ansabio.com/blog/better-biosecurity-for-dna-synthesis-in-the-ai-era/): Scott Fay, VP, Informatics Earlier this year I had the opportunity to participate in a panel discussion about AI and biosecurity at the annual SynBioBeta meeting. Those of us closest to this issue, including my colleagues and I at Ansa, feel a great sense of urgency about improving biosecurity practices for DNA synthesis. The prominence
- [Webinar: Codon Optimization Isn’t Equal - Benchmarking Gene Design for Antibody Expression](https://ansabio.com/news-events/events/webinar/): In this GEN webinar, Justin Byers and Daniel Lin-Arlow, PhD, examine how enzymatic DNA synthesis and DNA construct design mitigate antibody expression challenges. Register here.
- [What Is the Real Cost of DNA Synthesis?](https://ansabio.com/dna101/how-much-does-dna-synthesis-cost/): Discover the true cost of DNA synthesis, including key pricing factors like sequence length, turnaround time, customization, and provider differences.
- [What Is Codon Optimization and Why Should I Care?](https://ansabio.com/dna101/what-is-codon-optimization/): Learn what codon optimization is and how it supports DNA and protein engineering. Understand its role in improving expression and performance.
- [DNA Synthesis Was Broken. We Fixed It.](https://ansabio.com/blog/dna-synthesis-was-broken-we-fixed-it/): If your research depends on DNA, you know the frustration: sliding timelines, added fees, and the email no one wants to read — ‘One or more of your sequences failed synthesis…’
- [What If You Could Build Without Limits? With 50 kb DNA, Now You Can](https://ansabio.com/blog/what-if-you-could-build-without-limits-with-50-kb-dna-now-you-can/): Unlock new possibilities with 50 kb clonal DNA from Ansa. High-quality, ultra-long synthetic DNA—faster, affordable, and made in the USA.
- [Ansa Biotechnologies to Showcase Breakthrough DNA Synthesis Technology Backed by Industry’s Only On-Time Guarantee at SynBioBeta 2026 Conference](https://ansabio.com/news-events/pr/ansa-biotechnologies-to-showcase-breakthrough-dna-synthesis-technology-backed-by-industrys-only-on-time-guarantee-at-synbiobeta-2026-conference/): Direct, sequence-perfect clonal DNA up to 50 kb is empowering customers to expand their design space and innovate without compromise.
- [Ansa Biotechnologies Appoints Geoff Hamilton as Chief Financial Officer and Chief Business Officer](https://ansabio.com/news-events/pr/ansa-biotechnologies-appoints-geoff-hamilton-as-chief-financial-officer-and-chief-business-officer/): Mr. Hamilton will lead the company’s financial operations, corporate strategy, and key partnerships as Ansa accelerates its commercial expansion across the biotechnology, synthetic biology, and pharmaceutical sectors.
- [Ansa Biotechnologies Appoints Matthias Arenskötter as Chief Operating Officer](https://ansabio.com/news-events/pr/ansa-biotechnologies-appoints-matthias-arenskotter-as-chief-operating-officer/): Seasoned DNA synthesis executive will oversee expansion of production capacity to meet rising demand for high-quality long and complex DNA products backed by industry’s only service guarantee.
- [Ansa’s Enzymatic DNA Synthesis Technology: Where It All Began](https://ansabio.com/blog/ansas-enzymatic-dna-synthesis-technology-where-it-all-began/): Trace the origins of Ansa’s enzymatic DNA synthesis and its breakthrough TdT-based approach. See how it delivers longer, more accurate DNA with proven results.
- [Integrated DNA Technologies Expands Synthetic Biology Portfolio with Ansa Biotechnologies’ Clonal DNA and XL Clonal DNA Products](https://ansabio.com/news-events/pr/integrated-dna-technologies-expands-synthetic-biology-portfolio-with-ansa-biotechnologies-clonal-dna-and-xl-clonal-dna-products/): New collaboration empowers customers with sequence-perfect constructs as long as 50 kb.
- [Chemical vs. Enzymatic DNA Synthesis Techniques](https://ansabio.com/dna101/chemical-vs-enzymatic-dna-synthesis/): Compare chemical vs. enzymatic DNA synthesis. See how Ansa Bio’s enzymatic method delivers faster, greener, and more precise DNA production.
- [Ansa Biotechnologies Targets Nucleic Acid Synthesis Market With Ultra-Long Clonal DNA Service](https://ansabio.com/news-events/news/ansa-biotechnologies-targets-nucleic-acid-synthesis-market-with-ultra-long-clonal-dna-service/): Enzymatic DNA synthesis company Ansa Biotechnologies hopes to win a slice of the nucleic acid synthesis market with ultra-long DNA products that it believes are hard to obtain with traditional phosphoramidite-based chemical synthesis.
- [Ending The Waiting Game: How Ansa Biotechnologies Guarantees are Turning DNA Synthesis Into A Predictable Industry](https://ansabio.com/news-events/news/ending-the-waiting-game-how-ansa-biotechnologies-guarantees-are-turning-dna-synthesis-into-a-predictable-industry/): When Jason T. Gammack talks about DNA synthesis, he does not start with base chemistry or instrument design. He starts with broken promises. For decades, synthetic biology teams have designed pathways in hours, then waited weeks or months for gene fragments that arrived late, arrived wrong, or never arrived at all. Read the full article
- [Webinar: Complex DNA Synthesis for Your Most Ambitious Projects](https://ansabio.com/news-events/events/webinar-complex-dna-for-your-most-ambitious-projects/): This webinar covers Ansa's unique enzymatic approach to DNA synthesis, and how Ansa has been able to provide the Cress Lab at the Innovative Genomics Institute with access to their repetitive and complex DNA sequences that is further enabling their work in microbial engineering.
- [Webinar: Rewriting Cellular Communication](https://ansabio.com/news-events/events/webinar-rewriting-cellular-communication/): Join us in this webinar case study to discover ways to progress and iterate scientific work that were previously unimaginable. Get an exciting look at innovative platforms, such as the Retained Endoplasmic Cleavable Secretion (RELEASE) platform developed by Stanford’s Gao Lab.
- [Webinar: Revolutionizing Gene Therapies through Rapid, Large DNA Synthesis & Designable Delivery Vehicles](https://ansabio.com/news-events/events/webinar-revolutionizing-next-generation-gene-therapies/): In this joint webinar, EndoFold, Inc. and Ansa Biotechnologies share results from a proof-of-concept collaboration demonstrating a new path forward: ultra-rapid synthesis of full-length therapeutic constructs paired with next-generation, designable delivery vehicles.
- [Hate Rejection? So Do We. Here’s Why Ansa Can Make the Complex DNA Other Vendors Can’t.](https://ansabio.com/blog/hate-rejection-so-do-we-heres-why-ansa-can-make-the-complex-dna-other-vendors-cant/): Most companies struggle to reliably produce large, complex sequences, forcing scientists to settle for simpler, shorter fragments that can compromise their research.
- [For Gene Therapy Development, High-Quality Synthetic DNA Matters](https://ansabio.com/blog/for-gene-therapy-development-high-quality-synthetic-dna-matters/): Whether it’s for constructing transgene payloads or engineering viral vector delivery systems, researchers count on gene synthesis vendors throughout the discovery, development, and manufacturing journey.
- [Creating New Momentum in DNA Synthesis: Q&A with Ansa Founders](https://ansabio.com/blog/creating-new-momentum-in-dna-synthesis-qa-with-ansa-founders/): At Ansa, we’re fortunate to have not one but three scientific founders, all of whom are still with the company and helping to improve our synthesis technology with new innovations on a regular basis.
- [A New Era in DNA Synthesis: Introducing the Ansa On-Time Guarantee](https://ansabio.com/blog/a-new-era-in-dna-synthesis/): Today, we announced a transformation in our business model. Our new Ansa On-Time Guarantee shifts us from best-effort fulfillment to a bold, reliability-first approach — one that we hope will catalyze change across the entire DNA synthesis field.
- [Untangling the Complexities of Gene Synthesis for Longer, More Reliable DNA](https://ansabio.com/blog/untangling-the-complexities-of-gene-synthesis-for-longer-more-reliable-dna/): At Ansa, we’re on a mission to end the headaches of ordering synthetic DNA and give researchers what they really want: reliable DNA, on time, exactly as ordered.
- [When Choosing a DNA Synthesis Vendor, Consider the Metrics that Matter](https://ansabio.com/blog/when-choosing-a-dna-synthesis-vendor-consider-the-metrics-that-matter/): Learn how to select a DNA synthesis vendor by evaluating turnaround time, complexity, quality control, cost, and security with Ansa’s enzymatic DNA technology.
- [Ansa Is Proud to Support iGEM Teams. Check Out These Amazing Projects!](https://ansabio.com/blog/ansa-is-proud-to-support-igem-teams-check-out-these-amazing-projects/): When MIT scientists Drew Endy, Tom Knight, and Randy Rettberg held a month-long biological engineering program back in 2003, they probably never imagined that it would pave the way for the iGEM annual synthetic biology competition that has been going strong for more than two decades.
- [DNA Synthesis Explained: Steps, Enzymes, and Importance](https://ansabio.com/dna101/how-does-dna-synthesis-work/): Discover how DNA synthesis works, its steps, key enzymes, and its importance in biotechnology. Learn more!
- [Ansa Biotechnologies Redefines What’s Possible in DNA Synthesis with 50 kb Sequence-Perfect Clonal Product](https://ansabio.com/news-events/pr/ansa-biotechnologies-redefines-whats-possible-in-dna-synthesis-with-50-kb-sequence-perfect-clonal-product/): Ansa is the first to deliver ultra-long, fully verified DNA in less than 25 days, backed by the industry’s only on-time guarantee. View the press release.
- [Ansa Biotechnologies closes $54.4M Series B to boost US DNA manufacturing](https://ansabio.com/news-events/news/ansa-biotechnologies-closes-54-4m-series-b-to-boost-us-dna-manufacturing/): Ansa plans to use some of the funding to expand its facility in Emeryville, CA. The company will install an upgraded version of its technology which will make its DNA manufacturing more efficient. New manufacturing platforms will also be added at the Emeryville site to expand production capacity. Read the full story.
- [Ansa Biotechnologies Secures $54.4 Million in Series B Financing](https://ansabio.com/news-events/pr/ansa-biotechnologies-secures-54-4-million-in-series-b-financing/): Ansa Biotechnologies, Inc. today announced that it has closed $45.2 million and secured commitments for an additional $9.2 million as part of an oversubscribed series B financing round. View the press release.
- [Enzymatic Approaches Will Transform DNA Synthesis, but Which One Is Right for You?](https://ansabio.com/news-events/news/enzymatic-approaches-will-transform-dna-synthesis-but-which-one-is-right-for-you/): Read this editorial in Technology Networks by Ansa CSO and co-founder Dan Lin-Arlow to learn about the factors you should consider if you are looking to switch to enzymatic synthesis.
- [DNA Supplier Ansa Biotechnologies Snares $68 Million](https://ansabio.com/news-events/news/dna-supplier-ansa-biotechnologies-snares-68-million/): “Venture capitalists have supplied $68 million in fresh capital to Ansa Biotechnologies Inc., a startup that says it has developed a new way to produce DNA needed to develop medicines and other products made through genetic engineering.” ”Emeryville, Calif.-based Ansa says it has technology for writing genetic code that relies on enzymes instead of chemicals
- [Long-DNA Synthesis Gathers Momentum](https://ansabio.com/news-events/news/long-dna-synthesis-gathers-momentum/): An article in Nature features Ansa's Chief Scientific Officer and co-founder Dan Lin-Arlow discussing the unique capabilities of enzymatic DNA synthesis. Read the full story here.
- [Toward Genome Engineering at Massive Scale](https://ansabio.com/blog/toward-genome-engineering-at-massive-scale/): As costs fall, the question shifts from “What can we afford?” to “What can we imagine?”
- [Enabling New Access to Complex DNA for Vaccine Development](https://ansabio.com/blog/touchlight/): For scientists, getting access to complex DNA has historically been challenging. Scientists themselves, our founders experienced the frustrations first-hand, which is why they were driven to develop a more effective and efficient solution. In doing so, we are excited to work with companies like Touchlight, an innovation-led Contract Development and Manufacturing Organization (CDMO) in London,
- [Complex DNA Synthesis for Your Most Ambitious Projects](https://ansabio.com/blog/complex-dna-synthesis-for-your-most-ambitious-projects/): By delivering multiplexed CRISPR arrays and the newly characterized IS110 systems, Ansa enables editing multiple loci in genomes at once, dramatically increasing the rate of learning how multiple edits interact with one another.
- [From Nature to Nurture: The Ansa Origin Story](https://ansabio.com/blog/from-nature-to-nurture/): In 2018, Ansa co-founders Dan-Lin Arlow, “a computer kid” growing up, and Sebastian Palluk, an athlete turned biologist, published “De novo DNA synthesis using polymerase-nucleotide conjugates” in Nature Biotechnology.
- [Breaking Boundaries: How Ansa Is Revolutionizing Gene Synthesis with Long Oligos](https://ansabio.com/blog/breaking-the-boundaries-of-synthetic-dna/): Life science research has been limited for decades — not because of scientists’ ambitions but because of outdated technology.
- [Ansa Biotechnologies Pushes Limits of Complex DNA Synthesis with Launch of New Commercial Products](https://ansabio.com/news-events/pr/ansa-biotechnologies-pushes-limits-of-complex-dna-synthesis-with-launch-of-new-commercial-products/): Ansa Biotechnologies announced the commercial availability of its Ansa Clonal DNA and Ansa DNA Fragments. Ansa is the only company able to synthesize complete, contiguous DNA oligonucleotides as long as 600 bp without requiring assembly, delivering products as sequence-perfect clonal DNA or sequence-verified linear double-stranded DNA fragments. View the press release.
- [Advancing Enzymatic DNA Synthesis for DNA-Intensive Applications](https://ansabio.com/news-events/news/advancing-enzymatic-dna-synthesis-for-dna-intensive-applications/): Microsoft and Ansa researchers describe a new approach toward ultra-high throughput enzymatic DNA synthesis on a chip in ACS Synthetic Biology. The method could be useful for DNA-based data storage and Synthetic Biology applications.
- [Accelerating Life Science Projects: A Glimpse at the Next Generation of DNA Synthesis](https://ansabio.com/blog/accelerating-life-sciences/): Six years into our journey at Ansa Biotechnologies, we can proudly say that we have succeeded at building an enzymatic DNA synthesis technique superior to the prior gold standard, the phosphoramidite method.
- [Enzymatic DNA Synthesis: Shorter Waits, Longer Strands](https://ansabio.com/news-events/news/enzymatic-dna-synthesis-shorter-waits-longer-strands/): Ansa's enzymatic DNA synthesis is featured in Genetic Engineering & Biotechnology News.Read the article
- [Sharing Our Latest Advances with the Synthetic Biology Community](https://ansabio.com/blog/sharing-our-latest-advances-with-the-synthetic-biology-community/): The Ansa team was thrilled to participate in this year’s Global Synthetic Biology conference, better known to the community as SynBioBeta. It’s the leading annual event for the synthetic biology field, but for us, it has a more personal connection...
- [Ansa Biotechnologies Breaks Traditional Synthetic DNA Length Barriers and Redefines Future of Life Science Research](https://ansabio.com/news-events/pr/ansa-biotechnologies-breaks-traditional-synthetic-dna-length-barriers-and-redefines-future-of-life-science-research/): Ansa Biotechnologies, Inc., the trusted partner for DNA synthesis, today announced the launch of its 50 kb DNA synthesis early access program, providing customers with extremely long and complex DNA sequences in less than four weeks.
- [Ansa Biotechnologies Expands Successful Early Access Program for Complex DNA Synthesis](https://ansabio.com/news-events/pr/ansa-biotechnologies-expands-successful-early-access-program-for-complex-dna-synthesis/): Ansa Biotechnologies is expanding its early access program for its complex DNA synthesis services. More customers around the world will now be able to take advantage of the company’s innovative enzymatic DNA synthesis technology to accelerate innovation in healthcare, life science research, and other industries powered by synthetic DNA. View the press release.
- [Ansa Biotechnologies Sets New Standard in Long, Complex DNA](https://ansabio.com/news-events/pr/ansa-biotechnologies-sets-new-standard-in-long-complex-dna/): Combining its complex DNA synthesis platform with a unique long-read sequencing and analysis approach for quality control allows Ansa to produce long, complex DNA more accurately and reliably than any other DNA synthesis vendor. View the press release.
- [The Evolution of Codon Optimization: From Promise to Pragmatism](https://ansabio.com/blog/the-evolution-of-codon-optimization/): With Ansa's technology, researchers will now be able to more fully explore the complex relationship between coding sequence and function than has been possible in the past.
- [Accelerating the Pace of Drug R&D with Synthetic Biology](https://ansabio.com/news-events/news/accelerating-the-pace-of-drug-rd-with-synthetic-biology/): The importance of Ansa's technology to enable synthesis of complex DNA for advanced research is featured in this editorial from Biocompare.
- [Synthesizing the Rules: How DNA Got Its Groove Back](https://ansabio.com/news-events/news/synthesizing-the-rules-how-dna-got-its-groove-back/): Ansa Biotechnologies’ DNA synthesis technology and first product launch are featured in this story from SynbioBeta.
- [Long DNA for Difficult Applications - Dan Lin-Arlow](https://ansabio.com/news-events/news/long-dna-for-difficult-applications-dan-lin-arlow/): Dan Lin-Arlow discusses Ansa's groundbreaking de novo synthesis of the world's longest oligo and their proprietary method in a podcast with Theral Timpson on the Mendelspod podcast. Explore the challenges of synthesizing long DNA, the impact of computation and AI in DNA synthesis, and more. Subscribe to Mendelspod to listen to the full podcast.
- [Advancing DNA Writing Technologies for Synthetic Genomes](https://ansabio.com/news-events/news/advancing-dna-writing-technologies-for-synthetic-genomes/): Nature Biotechnology news feature on the promises and implications of new DNA synthesis technologies, featuring comments from Ansa Biotechnologies’ Dan Lin-Arlow.
- [Enzymatic DNA Synthesis: Going to Great Lengths](https://ansabio.com/news-events/news/enzymatic-dna-synthesis-going-to-great-lengths/): The Scientist article highlighting the need to move beyond chemical DNA synthesis in order to continue pushing science further. Featuring Ansa co-founder and Chief Science Officer, Dan Lin-Arlow.
- [Ansa Biotechnologies to Showcase Early Access Customer Success at Upcoming Global Synthetic Biology Conference](https://ansabio.com/news-events/pr/ansa-biotechnologies-to-showcase-early-access-customer-success-at-upcoming-global-synthetic-biology-conference/): Ansa Biotechnologies today announced its speaker lineup for presentations at the upcoming Global Synthetic Biology (SynBioBeta) Conference in San Jose, Calif., from May 6-9, 2024. Meeting attendees will be able to learn how to participate in the program throughout the conference in booth #312. View the press release.
- [Enzymatic DNA Synthesis Challenges the Gold Standard](https://ansabio.com/news-events/news/enzymatic-dna-synthesis-challenges-the-gold-standard/): In a GEN article, Julianna LeMieux discusses the challenge posed by enzymatic synthesis to the gold standard of DNA synthesis, phosphoramidite chemistry. Ansa CEO Dan Lin-Arlow shares insights on using TdT polymerase to achieve longer DNA, encouraging the pursuit of bold visions in DNA writing.
- [Ansa Biotechnologies Appoints Jason T. Gammack as CEO](https://ansabio.com/news-events/pr/ansa-biotechnologies-appoints-jason-t-gammack-as-ceo/): Gammack is joining the company as it completes its early access program and prepares for a full commercial launch of its rapid enzymatic synthesis for complex clonal genes and gene fragments. Founding CEO Dan Lin-Arlow, PhD, will remain with the company and transition to a new position as chief scientific officer. View the press release.
- [Ansa Bio Appoints Dr. Matthew McManus as Chair of the Board](https://ansabio.com/news-events/pr/ansa-bio-appoints-dr-matthew-mcmanus-as-chair-of-the-board/): Ansa Biotechnologies, a pioneer of next-generation DNA synthesis, today announced the appointment of Matthew F. McManus, M.D, Ph.D., as Independent Director and Chairperson of the company’s Board of Directors. Dr. McManus brings decades of experience in the life sciences industry to the Board. View the press release
- [Ansa Biotechnologies Closes Oversubscribed $68 Million Series A Financing to Power the Next Era of DNA-Enabled Industries](https://ansabio.com/news-events/pr/ansa-biotechnologies-closes-oversubscribed-68-million-series-a-financing-to-power-the-next-era-of-dna-enabled-industries/): Ansa’s next-generation enzymatic DNA synthesis technology will dramatically accelerate innovation across every industry enabled by synthetic DNA from biologic drugs to biomanufacturing, and DNA-based data storage. Funding will advance next-generation technology platform, expand R&D and manufacturing facilities, grow multidisciplinary team, and launch DNA synthesis service. Ansa is solving current industry bottlenecks associated with synthesizing complex
- [De novo DNA synthesis using polymerase-nucleotide conjugates](https://ansabio.com/news-events/news/de-novo-dna-synthesis-using-polymerase-nucleotide-conjugates/): First publication of an enzymatic method for the synthesis of novel DNA sequences, using an approach based on polymerase-nucleotide conjugates that have the ability to extend a DNA molecule by one building block at a time. The technology was featured, besides others, in a commentary article in Nature Biotechnology and Nature Methods, STAT News, Cosmos
- [New technique could help scientists create a gene in just one day](https://ansabio.com/news-events/news/new-technique-could-help-scientists-create-a-gene-in-just-one-day/): “Creating a new gene in a single day could soon be possible, thanks to a new technique that mimics the way the body copies its own DNA. Though the technology needs to clear a few more hurdles, it could one day let researchers speedily rewrite microbe genes, enabling them to synthesize new medicines and fuels
- [Four synthetic biology startups to watch in 2019](https://ansabio.com/news-events/news/four-synthetic-biology-startups-to-watch-in-2019/): “DNA synthesis is the cornerstone of synthetic biology and demand for the technology is growing at an unprecedented rate. California-based Ansa Biotechnologies is seeking to upend an industry that has relied on chemical processes for decades, providing accurate, clean, and, importantly –fast — DNA using enzymes instead of chemicals.” Read the full article.
- [The race for enzymatic DNA synthesis heats up](https://ansabio.com/news-events/news/the-race-for-enzymatic-dna-synthesis-heats-up/): “Those products could fill niches that chemistry cannot: long, complex sequences — synthetic gene libraries, for instance — for which assembly from shorter segments can add significant delays. “Any technology that can make that faster is going to be very valuable,” says Christopher Voigt, a synthetic biologist at the Massachusetts Institute of Technology in Cambridge.“
- [Ansa Biotechnologies Awarded Competitive Grant from the National Science Foundation](https://ansabio.com/news-events/news/ansa-biotechnologies-awarded-competitive-grant-from-the-national-science-foundation/): Ansa Biotechnologies has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $ 225,000 to conduct research and development (R&D) work on improved reagents for enzymatic DNA synthesis. “NSF is proud to support the technology of the future by thinking beyond incremental developments and funding the most creative, impactful ideas
- [Ansa Biotechnologies secures license for polymerase-nucleotide conjugates from UC Berkeley](https://ansabio.com/news-events/news/ansa-biotechnologies-secures-license-for-polymerase-nucleotide-conjugates-from-uc-berkeley/): The patent covers the core enzymatic DNA synthesis approach that will power Ansa’s nucleic acid manufacturing service. We are proud to work together with the University of California, Berkeley, to develop this technology further aiming to speed up research across all disciplines of biology and biotechnology.
- [The dawn of cheap and easy DNA writing](https://ansabio.com/news-events/news/the-dawn-of-cheap-and-easy-dna-writing/): “If there is better [synthesis through] enzyme chemistry, I’ll be the first customer.” Once the approach reaches one of any number of milestones—longer, fewer errors, or faster production—she’d be on board. “I’ll take cheaper but frankly I’ll pay more if it’s faster or better or longer.” -Emily LeProust Read the full article.
- [Technology feature - How to build a genome](https://ansabio.com/news-events/news/technology-feature-how-to-build-a-genome/): “The standard technique, called phosphoramidite synthesis, is decades old and struggles to produce sequences longer than about 200 bases; anything bigger must be created by linking the fragments together. Enzymatic synthesis methods are a promising alternative. In 2018, for instance, researchers led by synthetic biologist Jay Keasling and his then-PhD student Daniel Arlow at the
- [Ansa Biotechnologies Raises $9.2 Million in Combined Seed and Pre-Seed Financing](https://ansabio.com/news-events/pr/ansa-biotechnologies-raises-9-2-million-in-combined-seed-and-pre-seed-financing/): “Ansa Biotechnologies today announced that it has raised $7.9 million in an oversubscribed Seed round of funding led by Horizons Ventures, with participation from Mubadala Capital, Humboldt Fund, and additional investors. Combined with a Pre-Seed round raised in December 2018 led by Fifty Years, the company has raised $9.2 million to date.…” View the press
- [Ansa Biotechnologies wants to usher in a new era of DNA manufacturing](https://ansabio.com/news-events/news/ansa-biotechnologies-wants-to-usher-in-a-new-era-of-dna-manufacturing/): “It’s also important to note that Arlow’s company is doing synthesis as a service rather than selling bioprinters that can enable any researcher to make their own DNA. ‘One of the reasons we’re developing our business as a DNA synthesis service… as opposed to making a printer… is because that gives us a much greater
- [Enzymatic DNA synthesis enters new phase](https://ansabio.com/news-events/news/enzymatic-dna-synthesis-enters-new-phase/): “But more generally, these short sequences are just a stepping stone toward being able to generate the long sequences that are currently out of reach with chemical synthesis. ‘We’re trying to make thousand-mers and make those into genes,’ says Arlow. Beyond synthetic biology, this could also help accelerate the production of nucleic acid-based vaccines or
- [Ansa Biotechnologies partners with TeselaGen Biotechnology to enable commercial production of DNA products](https://ansabio.com/news-events/pr/ansa-biotechnologies-partners-with-teselagen-biotechnology-to-enable-commercial-production-of-dna-products/): “Ansa Biotechnologies Inc., the company developing a new way to make DNA using enzymes, is announcing a partnership with TeselaGen Biotechnology Inc., the company developing an integrated enterprise software operating system for designing, building, and optimizing biological and biochemical products. The partnership will bring a broad set of tools to Ansa Biotechnologies that will bolster
- [Ansa Biotechnologies Awarded NSF SBIR Phase II Grant](https://ansabio.com/news-events/news/ansa-biotechnologies-awarded-nsf-sbir-phase-ii-grant/): Building from a successful Phase I, Ansa will continue to develop and scale its enzymatic method for DNA synthesis with support from the National Science Foundation. Ansa’s technology enables a new DNA manufacturing process that promises to provide synthetic DNA to researchers in record time, accelerating biotechnology broadly.
- [Ansa Biotechnologies collaborates with Microsoft Research to help unlock scalable and sustainable DNA data writing technology](https://ansabio.com/news-events/news/ansa-biotechnologies-collaborates-with-microsoft-research-to-help-unlock-scalable-and-sustainable-dna-data-writing-technology/): “Synthetic DNA, at its root a tiny storer of information, offers a potential pathway toward significantly reducing the amount of space and material needed for future archival storage needs… DNA can be incredibly durable and can last thousands of years, unlike tape, which needs to be rewritten every 30 years at best.” ”We’re also working
- [Ansa Biotechnologies Announces Successful de novo Synthesis of World’s Longest Oligonucleotide at 1005 Bases](https://ansabio.com/news-events/pr/ansa-biotechnologies-announces-successful-de-novo-synthesis-of-worlds-longest-oligonucleotide-at-1005-bases/): The next frontier in oligonucleotide synthesis is the direct synthesis of gene-length sequences. Ansa synthesized a 1005 base long oligonucleotide with industry-leading accuracy. Ansa will be initiating an Early Access Program for clonal synthetic genes in April 2023 to help researchers obtain sequences that have been difficult to synthesize “The 1005 base sequence encodes a
- [Ansa Biotechnologies Announces First Shipments of Complex Clonal DNA Sequences to Customers in its Early Access Program](https://ansabio.com/news-events/pr/ansa-biotechnologies-announces-first-shipments-of-complex-clonal-dna-sequences-to-customers-in-its-early-access-program/): Ansa successfully synthesized and delivered challenging promoter sequences with high GC and AT content to its first Early Access customer, Enoda, which were used to engineer gene expression. Ansa’s proprietary next-generation enzymatic DNA synthesis technology overcomes the limitations of traditional methods, giving scientists access to accurate complex DNA, quickly and reliably. View the press release.
- [Ansa Pioneers Enzymatic DNA Synthesis for Synthetic Biology Innovation](https://ansabio.com/news-events/news/ansa-pioneers-enzymatic-dna-synthesis-for-synthetic-biology-innovation/): Article in Forbes by John Cumbers, founder of SynBioBeta, tracing Ansa's journey from concept to successful synthesis of the world's longest oligonucleotide, showcasing their unique DNA synthesis technology and vision for the future of the industry.

## Pages

- [Custom DNA Synthesis](https://ansabio.com/): Unlock scientific breakthroughs with our custom DNA synthesis. As a leading enzymatic DNA synthesis company, we deliver speed, accuracy, and longer sequences for biology innovation.
- [Vector Library](https://ansabio.com/products/vector-library/): Find the right vector for cloning, mammalian, AAV and transcription projects. Our library offers plasmids for complex sequences and high performance.
- [Frequently Asked Questions](https://ansabio.com/resources/frequently-asked-questions/): Products and Services What synthesis services does Ansa offer? Ansa offers direct, contiguous synthesis of double stranded DNA up to 900 bp, and clonal DNA up to 50 kb. Our innovative technology enables us to deliver complex DNA sequences that are often challenging or impossible for other providers to synthesize. At the same time, our
- [Downloads](https://ansabio.com/resources/downloads/): Product Information DNA Antibody Grammar Language Case StudyLearn about Protein Coding Sequence grammar - subtle patterns in codon choice, repeats, and GC content shape how efficiently a cell can read and produce them.Download Case Study DNA Synthesis for the AI EraThis comprehensive guide explores how enzymatic DNA synthesis is rewriting the playbook for reliability, sequence complexity, and
- [The Ansa Team](https://ansabio.com/company/team/): We’re proud of our highly interdisciplinary team and their incredible accomplishments in developing Ansa’s innovative technology. Jason T. Gammack Chief Executive Officer Jason Gammack brings more than 30 years of leadership experience in the life sciences industry, with a proven track record of building and scaling high-impact biotechnology businesses. Prior to joining Ansa, he co-founded
- [Terms and Conditions](https://ansabio.com/terms-and-conditions/): Ansa Biotechnologies Terms of Sale These Terms of Sale are entered into by and between Ansa Biotechnologies, Inc. (“Ansa”) and customer (“Customer”). Customer agrees to accept and be bound by the following terms and conditions, together with any documents they expressly incorporate by reference (collectively, this “Agreement”). Please read these Terms of Sale carefully before you
- [ESGCT](https://ansabio.com/esgct/): ESGCT Annual Meeting Booth C-08 When your science pushes the limits, your DNA should keep up. How far can your DNA take you? New to Ansa? We’re the DNA synthesis company built to remove one of the biggest bottlenecks in gene and cell therapy research: waiting on DNA that arrives late, incomplete, or not quite
- [DNA Fragments](https://ansabio.com/products/dna-fragments/): Accelerate your research with sequence‑verified DNA fragments up to 900 bp. Our ds fragments integrate easily and ship quickly for complex sequences.
- [50kb Clonal DNA](https://ansabio.com/products/50kb/): Break length barriers with XL clonal DNA synthesis up to 50 kb. Our long DNA capabilities provide assembled sequences with low pricing and fast turnaround.
- [Clonal DNA](https://ansabio.com/products/clonal-dna/): Explore clonal DNA synthesis for sequence‑perfect constructs up to 7.5 kb. Our enzymatic process delivers accurate DNA quickly to accelerate your research.
- [DNA Fragments & Clonal DNA Products](https://ansabio.com/products/): Fast, reliable gene synthesis from DNA fragments (≤600 bp) to clonal DNA (≤7.5 kb) and ultra-long constructs (7.5–50 kb).
- [ASHG](https://ansabio.com/ashg/): ASHG Annual Meeting 2026 Booth #1303 When your science pushes the limits, your DNA should keep up. How far can your DNA take you? New to Ansa? We’re the DNA synthesis company built to remove one of the biggest bottlenecks in genetics research: waiting on DNA that arrives late, incomplete, or not quite right. Our
- [Synthesis Add Ons](https://ansabio.com/add-ons/): Your DNA arrives exactly as designed. Now take it further. Synthesis Add Ons to streamline your workflow. Sequence-perfect DNA is the starting point, not the finish line. Once your DNA arrives, the next steps are usually the same across every project: bank the clone so you don't have to re-order it and scale up enough
- [Ansa On-Time Guarantee](https://ansabio.com/guarantee/): Ensure your science is only limited by what’s possible, not what your vendor can handle. Ansa's On-Time Guarantee: your complete order on time, or it’s free.
- [Custom Vector Onboarding Early Access](https://ansabio.com/products/vector/): Custom Vector Onboarding Early Access Jump-start your research with Ansa’s vector onboarding, now available in Early Access. Our new program removes the traditional pain points of plasmid onboarding, letting you focus on discovery, not logistics. No Shipping Required: Eliminate the need to send physical DNA or plasmids. Simply upload your sequence file and Ansa will
- [Get Free DNA from Ansa for iGEM](https://ansabio.com/igem/): 20 kb x 20 Teams.Free Clonal DNA. SUBMISSION WINDOW: MAY 25 – AUG 7, 2026 20 kb x 20 Teams.Free Clonal DNA. SUBMISSION WINDOW: MAY 25 – AUG 7, 2026 Ansa is proud to support the 2026 iGEM competition by providing up to 20 kb of clonal synthetic DNA to 20 selected teams! Does your
- [Contact](https://ansabio.com/company/contact/): Contact Us We are happy to answer your questions about our company, technology, products or partnering opportunities. Please submit the form below and we will get back to you as soon as possible. For customer support, please complete our support form. If you are interested in a career with us, please visit our Careers page.
- [Synthetic Biology Applications](https://ansabio.com/applications/): Explore gene synthesis applications such as cell & gene therapy, vaccine development, CRISPR, and synthetic biology with Ansa’s enzymatic DNA synthesis.
- [Enzymatic DNA Synthesis Technology](https://ansabio.com/technology/): Discover the power of our enzymatic DNA synthesis technology. Create complex DNA damage-free, efficiently & accurately. Consult with us today!
- [Careers](https://ansabio.com/company/careers/): Join Us in Revolutionizing DNA Synthesis At Ansa, we're building revolutionary DNA synthesis technologies to transform life sciences research. We believe that the biggest challenges our world faces will be solved using biotechnology and that DNA synthesis will fuel that innovation. If you're passionate about pushing the boundaries of science and making a global impact,
- [Post-Qualification Vector Onboarding Survey](https://ansabio.com/vectors-onboarding/): Thank you for your interest in our Vector Onboarding Early Access program. Please complete the information below and we will reach out with more information on your vectors. If submitting multiple vectors, please submit multiple forms.
- [Codon Optimization Isn’t Equal: Benchmarking Gene Design for Antibody Expression](https://ansabio.com/codon-optimization-isnt-equal-benchmarking-gene-design-for-antibody-expression/): Webinar Codon Optimization Isn’t Equal: Benchmarking Gene Design for Antibody Expression On-demand Webinar Watch the Webinar Key takeaways include: An AI-powered codon optimization strategy that measurably improves transient antibody expression yield Why controlled side-by-side benchmarking under standardized conditions is the only reliable way to objectively evaluate DNA construct design choices How integrating rigorous sequence evaluation
- [Watch Axio Webinar](https://ansabio.com/watch-axio-webinar/)
- [DNA Synthesis for the AI Era](https://ansabio.com/resources/ebook/): DNA Synthesis for the AI Era Demand for longer, more complex DNA sequences is soaring. Here’s how to keep up. Synthetic DNA is powering transformational advances across biotech, pharma, and agriculture—but traditional methods can’t keep up with today’s demands. We’re excited to share a comprehensive new guide that explores how enzymatic DNA synthesis is rewriting
- [ASGCT](https://ansabio.com/asgct/): How far can your dna take you? When your science pushes the limits, your DNA should keep up. Join us for cocktails and conversation as we explore what it takes to move your science further. Cocktails • Hors d’oeuvres • Science Wednesday, May 137:00 – 8:30 PM Aloft HotelRoom: Mahoney Ex:Change403 D St, Boston, MA
- [Videos](https://ansabio.com/resources/videos/): Complexity DeliveredJaymin Patel, PhD, from the Cress Lab at The Innovative Genomics Institute, shares how Ansa has been able to deliver complex sequences that other vendors have rejected, further enabling his work.
- [Leading DNA Synthesis Company](https://ansabio.com/company/): We are a leading enzymatic DNA synthesis company empowering breakthroughs in synthetic biology, biotech, & pharma. Innovating to overcome traditional limits, we help scientists solve global health & sustainability challenges.
- [Expanding Access to Complex DNA](https://ansabio.com/expanding-access-to-complex-dna/): Tech Note Download Expanding Access to Complex DNA Advances in enzymatic DNA synthesis are changing what is possible. In this tech note, we share data demonstrating high success rates across sequences that are traditionally difficult to synthesize, including: Extreme GC content regions Promoters and 5’ UTRs AAV inverted terminal repeats Sequences with repeats and homopolymers
- [Webinar: Revolutionizing Gene Therapies through Rapid, Large DNA Synthesis & Designable Delivery Vehicles](https://ansabio.com/watch-revolutionizing-next-generation-gene-therapies/)
- [Revolutionizing Gene Therapies through Rapid, Large DNA Synthesis & Designable Delivery Vehicles](https://ansabio.com/revolutionizing-next-generation-gene-therapies/): On-demand Webinar Register To Watch Breakthroughs in gene therapy depend on the ability to build and deliver large, complex DNA constructs quickly, reliably, and at scale. Yet constructs over 5 kb, or those containing LTRs and intricate genomic elements, continue to strain traditional synthesis methods. Even once you have the DNA, today’s go-to delivery vehicles
- [Webinar: Complex DNA for Your Most Ambitious Projects](https://ansabio.com/webinar/): Complex DNA Synthesis for Your Most Ambitious Projects On-demand Webinar Register To Watch Current DNA synthesis technology relies on chemistry that damages DNA during its synthesis, leading to limited oligonucleotide length, unreliability and failure to deliver complex DNA. In this webinar, we discuss the new Ansa DNA Fragments and Ansa Clonal DNA products, that offer
- [Rewriting Cellular Communication - Advances in Synthetic Biology through Enzymatic DNA Synthesis for Protein Regulation](https://ansabio.com/webinar-rewriting-cellular-communication-advances-in-synthetic-biology-through-enzymatic-dna-synthesis-for-protein-regulation/): On-demand Webinar Register To Watch In recent years, mammalian synthetic biology has made significant strides, especially in controlling gene expression and designing complex cellular behaviors. Researchers have now begun to apply these principles at the protein level as well, enhancing control over secreted protein components. Join us in this webinar case study to discover how
- [Resources](https://ansabio.com/resources/): Access Ansa Biotechnologies resources: blogs, FAQs, downloads, and videos showcasing our enzymatic DNA synthesis technology.
- [DNA Synthesis 101](https://ansabio.com/resources/dna-synthesis-101/): DNA Synthesis 101
- [Helix Rush](https://ansabio.com/resources/helix-rush/)
- [Early Access Programs](https://ansabio.com/products/early-access/): product details catalog vectors On-time guarantee early access programs Early Access Programs Streamline your plasmid onboarding with Ansa's Vector Early Access program. Whether you’re pushing the boundaries of DNA synthesis or seeking a seamless plasmid onboarding experience, our new offerings are designed to remove barriers and empower your research. Explore both programs below to find
- [Product Table Test](https://ansabio.com/privacy-policy/test/): Two Flexible Formats Ansa offers complex DNA sequences in both sequence-perfect clonal DNA or sequence-verified linear double-stranded DNA fragment formats. Ansa Clonal DNA and Ansa DNA Fragments are easy to use and to integrate into your experimental workflows. *Early Access products are not included in the Ansa On-Time Guarantee. *Early Access products are not included
- [Blog](https://ansabio.com/resources/blog/): Discover cutting-edge insights and expert advice on DNA synthesis, biotechnology, and lab innovations. Stay informed & accelerate your research with our blog.
- [Opt-out preferences](https://ansabio.com/opt-out-preferences/)
- [Webinar: Rewriting Cellular Communication](https://ansabio.com/webinar-rewriting-cellular-communication/)
- [Customer Support](https://ansabio.com/customer-support/): Thank you for considering Ansa for your complex DNA synthesis needs. We are pleased to provide free service consultations and strive to provide excellent support to all our customers. For reference, please see our terms & conditions for product orders. Please complete this form if you would like to hear from a customer service representative.
- [Webinar: Complex DNA Synthesis for Your Most Ambitious Projects](https://ansabio.com/webinar/webinar-complex-dna-synthesis-for-your-most-ambitious-projects/)
- [Privacy Policy](https://ansabio.com/privacy-policy/): GENERAL STATEMENT Ansa Biotechnologies, Inc. (“Ansa,” “we,” “us,” or “our”) provides on-demand DNA synthesis services. This Privacy Policy is designed to help you understand how we collect, use, process, and share your personal information, and to help you understand and exercise your privacy rights. 1. SCOPE This Privacy Policy applies to personal information processed by

## Vectors

- [pANSA-Kan-v1.5](https://ansabio.com/vector/pansa-kan-v1-5/)
- [pIVT-Amp-120-v2.2](https://ansabio.com/vector/pivt-amp-120-v2-2/)
- [pStable-Ind-Amp-v1.0](https://ansabio.com/vector/pstable-ind-amp-v1-0/)
- [pAAV2-Amp-v2.1](https://ansabio.com/vector/paav2-amp-v2-1/)
- [pAAV2-Kan-v2.1](https://ansabio.com/vector/paav2-kan-v2-1/)
- [pCMV-Amp-v1.0](https://ansabio.com/vector/pcmv-amp-v1-0/)
- [pANSA-Amp-v1.5](https://ansabio.com/vector/pansa-amp-v1-5/)
- [pUC-Amp-v1.0](https://ansabio.com/vector/puc-amp-v1-0/)
- [pUC-Kan-v1.0](https://ansabio.com/vector/puc-kan-v1-0/)
- [pET-Amp-v1.0](https://ansabio.com/vector/pet-amp-v1-0/)
- [pET-Kan-v1.0](https://ansabio.com/vector/pet-kan-v1-0/)
- [pStable-Ind-Kan-v1.0](https://ansabio.com/vector/pstable-ind-kan-v1-0/)
- [pAnsa3 (Kan)](https://ansabio.com/vector/pansa3-kan/)
- [pAAV2-Amp-v2.0](https://ansabio.com/vector/paav2-amp-v2/)
- [pCMV-Amp-v1.1](https://ansabio.com/vector/pcmv-amp-kan-v1-1/)
- [pAnsa-Kan-v4](https://ansabio.com/vector/pansa-kan-v4/)

## Categories

- [Blog](https://ansabio.com/topic/blog/)
- [Events](https://ansabio.com/topic/news-events/events/)
- [Press Releases](https://ansabio.com/topic/news-events/pr/)
- [In the News](https://ansabio.com/topic/news-events/news/)
- [News & Events](https://ansabio.com/topic/news-events/)
- [DNA Synthesis 101](https://ansabio.com/topic/dna101/)